Tonix Pharmaceuticals Entered Agreement With Defense Threat Reduction Agency For $34M To Develop Broad-Spectrum Antiviral, TNX-4200, Through Phase 1 Clinical Evaluation
Tonix Pharmaceuticals Entered Agreement With Defense Threat Reduction Agency For $34M To Develop Broad-Spectrum Antiviral, TNX-4200, Through Phase 1 Clinical Evaluation
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.